9,800 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Acquired by Erste Asset Management GmbH

Erste Asset Management GmbH acquired a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 9,800 shares of the company’s stock, valued at approximately $37,000.

A number of other hedge funds have also recently added to or reduced their stakes in ZNTL. Anfield Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter valued at approximately $40,000. Aigen Investment Management LP acquired a new stake in Zentalis Pharmaceuticals in the third quarter valued at approximately $41,000. Capstone Investment Advisors LLC acquired a new stake in Zentalis Pharmaceuticals in the third quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. grew its stake in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after acquiring an additional 5,333 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter valued at approximately $58,000.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ZNTL shares. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Guggenheim cut their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price on the stock in a research report on Monday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $3.39 on Thursday. The firm has a market cap of $241.57 million, a PE ratio of -1.36 and a beta of 1.84. The stock’s fifty day moving average price is $3.34 and its two-hundred day moving average price is $4.65. Zentalis Pharmaceuticals, Inc. has a 1 year low of $2.66 and a 1 year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. Sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.